Ali Rizvi to Glucagon-Like Peptide-1 Receptor
This is a "connection" page, showing publications Ali Rizvi has written about Glucagon-Like Peptide-1 Receptor.
Connection Strength
1.052
-
Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014; 20(31):4953-60.
Score: 0.450
-
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
Score: 0.191
-
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020 10; 111:154343.
Score: 0.178
-
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.
Score: 0.153
-
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):494-496.
Score: 0.044
-
Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. Diabetes Obes Metab. 2017 05; 19(5):613-614.
Score: 0.035